Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.77 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.77 |
| ▸ | CA1 | P00915 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA7 | P43166 | 2/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.58 |
| ▸ | GRM7 | Q14831 | 4/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | IDO1 | P14902 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595323 | 1.00 | MTNR1A (0.77) | MTNR1AMTNR1BCA1CA2CA12 | |
| SCHEMBL1970413 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL1970411 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL8406961 | 0.83 | MTNR1A (0.57) | MTNR1AMTNR1BCA1CA2CA12 | |
| SCHEMBL9851524 | 0.81 | GRM7 (0.59) | MTNR1AMTNR1BCA1CA2GRM7 | |
| SCHEMBL6502466 | 0.80 | MEN1 (0.55) | MTNR1AMTNR1BGRM7IDO1MAPT | |
| SCHEMBL14242684 | 0.80 | MEN1 (0.55) | MTNR1AMTNR1BGRM7IDO1MAPT | |
| SCHEMBL9505624 | 0.80 | CA1 (0.63) | MTNR1AMTNR1BCA1CA2CA12 | |
| SCHEMBL23230039 | 0.79 | MTNR1A (0.53) | MTNR1AMTNR1BCA1CA2CA12 | |
| SCHEMBL4830429 | 0.79 | EPHX2 (0.68) | MTNR1AMTNR1BCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817294-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | Amgen Inc. (US) | 2007-08-15 | — | — | EP | claimed |
| EP-1633715-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | claimed |
| WO-2006019975-A1 | 1,2,3,4-TETRAHYDROPYRAZIN-2-YL ACETAMIDES AND THEIR USE AS BRADYKININ ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION RELATED DISORDERS | AMGEN INC. (US) | 2006-02-23 | — | — | WO | claimed |
| WO-2004108676-A1 | 2-(6-AMINO-PYRIDIN-3-YL)-2-HYDROXYETHYLAMINE DERIVATIVES AS BETA 2-ADRENOCEPTORS AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | claimed |
| EP-4642455-A1 | METHOD OF TREATING TAUOPATHIES | GT Gain Therapeutics SA (CH) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024141998-A1 | METHOD OF TREATING TAUOPATHIES | GT GAIN THERAPEUTICS SA (CH) | 2024-07-04 | — | — | WO | disclosed |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-10-12 | — | — | US | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| EP-0377977-A1 | Glycine derivatives and preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1990-07-18 | — | — | EP | disclosed |
| US-4929754-A | CARDIOVASCULAR DISORDERS, ANTICOAGULANTS, ANTITUMOR AGENTS | DR. KARL THOMAE GMBH (DE) | 1990-05-29 | — | — | US | disclosed |
| EP-0330380-A2 | Novel indanoxyacetic acid derivatives and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
| CN-1033800-A | Indan derivative and its preparation method | TANABE SEIYAKU CO (JP) | 1989-07-12 | — | — | CN | disclosed |
| EP-0317321-A2 | Indan derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1989-05-24 | — | — | EP | disclosed |
| US-4820705-A | ANTITUMOR, CARDIOVASCULR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1989-04-11 | — | — | US | disclosed |
| EP-0253321-A2 | Benzenesulfonamido-indanyl-compounds, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-01-20 | — | — | EP | disclosed |
| US-4192888-A | Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase | SMITHKLINE CORPORATION (US) | 1980-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | MTNR1A 2717/4885MTNR1B 1444/4885CA1 1164/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | MTNR1A 2717/4885MTNR1B 1444/4885CA1 1164/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MTNR1A 823/4885MTNR1B 815/4885CA1 3792/4885 |
| US-20230322722-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | MTNR1A 2978/4885MTNR1B 2969/4885CA1 4872/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MTNR1A 773/4885MTNR1B 747/4885CA1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.